Medical device industry insiders may very well remember 2019 as the year that IPOs came back — but another sign that the U.S. economy has left the Great Recession far behind. Among the top investment deals in the space, half involved public offerings, according to the MoneyTree report from PricewaterhouseCoopers (PwC) and CB Insights. Total investments […]
Ablative Solutions
Ablative Solutions touts study of its infusion catheter for renal denervation
Ablative Solutions announced today that it received positive results at six months from its post-market study for the Peregrine System infusion catheter, which accomplishes renal denervation by delivering microdoses of dehydrated alcohol. The results from the study of the safety and efficacy of the CE-Marked Peregrine System have been published in the Journal of the […]
ESC Congress: Study shows bariatric surgery can improve cardiac outcomes in Type 2 diabetes
Bariatric or metabolic surgery can significantly lower the risk of major cardiovascular events among patients with Type 2 diabetes and obesity, according to a new clinical study released at the European Society of Cardiology Congress in Paris. The retrospective study followed 13,722 Type 2 diabetes patients who underwent bariatric surgery to lose weight or metabolic […]
Ablative Solutions taps medtech vet Rumrill for CEO | Personnel Moves, July 16, 2019
Ablative Solutions tapped 30-year industry veteran Kate Rumrill, the former chief executive at NeoSync, to be its new president & CEO. Rumrill, whose resume includes stints at Covidien, Aspect Medical Systems and Eli Lilly, is slated to keep her seat on NeoSync’s board, San Jose, Calif.-based Ablative Solutions said. The company makes the Peregine renal […]
Ablative Solutions closes $77m Series D
Ablative Solutions said today that it closed a $77 million Series D funding round to help support its technology platform intended to treat hypertension. The round was led by newly invested Gilde Healthcare and co-led by existing investor BioStar Ventures and an undisclosed new strategic corporate investor, the Kalamazoo, Mich.-based company said. Existing investors Michigan […]
Infusion catheter developer Ablative Solutions raises $4m
Delaware-based Ablative Solutions has raised $4 million as part of a $10 million round, according to regulatory filings. The company is developing the Peregrine System, an infusion catheter that delivers diagnostic and therapeutic agents to the perivascular space surrounding blood vessels. The 510(k)-cleared device includes three microneedles that remain within radiopaque guide tubes prior to drug delivery. After […]
Ablative Solutions wins FDA nod for Phase II chemical denervation trial
Ablative Solutions said today that the FDA approved a Phase II trial of its chemical denervation system for hypertension under its investigational new drug application. The trial, called Target-BP I, will evaluate the efficacy of Ablative’s Peregrine infusion ablation system, which uses ethanol to interrupt signals from sympathetic nerves in the renal artery to control […]
Ablative Solutions raises $2.4m, looks for $4m more
Ablative Solutions has pulled in $2.4 million in a new round of financing, looking to raise another $4 million in the round, according to an SEC filing posted last week. The Kalamazoo, Mich.-based company developed and produces the Peregrine infusion ablation catheter for treating hypertension. The Peregrine system infuses neurolytic agents into the perivascular space […]
Renal denervation: Ablative Solutions wins CE Mark for chemical ablation catheter
Ablative Solutions said it received CE Mark approval for its Peregrine infusion ablation catheter for treating uncontrolled hypertension. The company began testing Peregrine last year in Poland.
Ablative Solutions tests infusion ablation catheter as hypertension treatment
Hypertension: Ablative Solutions lands $8M for renal denervation tech
Ablative Solutions, which is developing perivascular renal denervation technology for treating high blood pressure, raised an $8.0 million funding round, according to a regulatory filing.
Menlo Park, Calif.-based Ablative Solutions said 98 unnamed investors participated in the funding round, which consisted of debt, options and warrants.
